Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

USA Continuing Claims for Sept 24 2.714M vs 2.780M Est; Prior 2.802M

USA Continuing Claims for Sept 24 2.714 million vs 2.780 million consensus estimate. The prior reading was 2.802 million.
byBenzinga Newsdesk
October 7, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

USA Continuing Claims for Sept 24 2.714 million vs 2.780 million consensus estimate. The prior reading was 2.802 million.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

ALX Oncology Announced Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine at ASH 2021; Said Complete Remissions With Cytogenetic Responses, Hematologic Improvement, and Transfusion Independence Were…

By Charles Gross
Today, 10:43 AM
ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients wi

ALXO